Improving the lives of patients is our mission. We are an ambitious and dynamic business with a healthy innovation-driven pipeline that enables us to build on our core expertise in pain. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. This commitment to innovation and thought-leadership means that next generation scientific talent is drawn to us.
Grünenthal. Change is possible.
We are present in 30 countries with affiliates in Europe, Latin America and the US.
Our products are sold in more than 100 countries.
5,200 employees work for our group worldwide.
Featured news & articles
Aachen, Germany, 5 November 2018 – Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza® (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grünenthal is now the sole owner of Qutenza® worldwide, including the US, Latin America, Asia and Australia. Grünenthal had already acquired exclusive commercial rights for Europe, Middle East and Africa in December 2016.
Aachen, Germany, 30 October 2018 – Grünenthal today announced that it has agreed to acquire AstraZeneca’s European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m (€ 811 m). Nexium (esomeprazole) is a proton pump inhibitor (PPI) that helps to reduce the amount of acid produced by the stomach in patients with gastroesophageal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). Vimovo is a fixed-dose combination tablet of naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium. It is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric and/or duodenal ulcers.
Aachen, Germany, 9 October 2018 – Kerstin Nacken took over the newly created position "Head Editorial Management and Media Relations" at Grünenthal on 1 September 2018. In this function she is responsible for all media related activities of the research-based pharmaceutical company and heads the editorial team for internal and external corporate channels.
Aachen, Germany, 28 August 2018 – Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of hyperuricaemia in adult gout patients who have not been able to reach target levels of uric acid serum with a dose of allopurinol alone. Lesinurad is the first innovative uricosuric in gout treatment for over 40 years.
Aachen, Dortmund and Göttingen, Germany, June 21, 2018 – Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited neurological disorder. The collaboration combines the disease proficiency of MPI-EM, the drug discovery expertise of LDC and Grünenthal’s competency in drug discovery and development as well as pain management. The project’s scientific foundation was laid at MPI-EM by Michael Sereda, Klaus-Armin Nave and Moritz Rossner.
Diegem/Aachen, 18 June 2018. The number of patients suffering from pain is immense. In a recent ‘European Pain Management’ publication (Oxford University Press, 2018), Christopher Eccleston, Bart Morlion and Christopher Wells shared that of approximately 740 million people in the 37 member states of the European Pain Federation EFIC®, approximately 150 million people suffer from chronic pain. This number is equivalent to the populations of both France and Germany combined. The data clearly highlight that pain research is more important than ever. Through the support of the E-G-G Award, young scientists are encouraged to further develop and implement their research ideas.